Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01909271 · ClinicalTrials.gov registry record · NA

Tailored Approaches to Stroke Health Education

A NA study, sponsored by Columbia University.

Completed
Registry status
NA
Development phase
290
Enrollment target

NCT01909271: Completed NA study, sponsored by Columbia University.

NCT01909271 is a NA study that has completed, run by Columbia University. The registered enrollment target is 290 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01909271, a NA study, has completed, sponsored by Columbia University.

COMPLETED
Registry status
NA
Development phase
290 participants
Enrollment target

Study Summary

The overarching goal of the proposed intervention is to reduce stroke disparities by overcoming pre-hospital barriers related to emergency stroke treatment and facilitating the appropriate response to acute stroke using a novel culturally-tailored and sustainable approach developed by an experienced transdisciplinary team. Building on our previous work, in which the investigators have identified barriers to increasing stroke literacy and behavioral intent to call 911, the investigators will develop and evaluate the effectiveness of a novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-minute films (in English and Spanish), in minority populations in New York City (NYC). Behavioral intent to call 911 will be assessed immediately after viewing the film, 6 months later, and one year later.

Primary Outcome

The Stroke Action Test (STAT) contains 21 items that name or describe stroke symptoms from all 5 groups of warning signs and 7 items that are nonstroke symptoms. For each item, the respondent selects 1 of 4 options: call 911, call doctor, wait 1 hour, or wait 1 day. For scoring purposes, each correct response receives 1 point; incorrect responses receive 0 points. The total score is reported as percent of correct responses. Scores range from 0% to 100% with a higher score indicating a better out

Interventions

  • BEHAVIORAL Stroke Education Film Viewing
  • OTHER Stroke Education Pamphlet Exposure

Trial Details

FieldValue
Enrollment Target 290 participants
Start Date 2014-04-16
Est. Completion 2019-12
Phase NA
Columbia University

958 total trials

What the finished NCT01909271 record still lists

NCT01909271 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 2 interventions - of which Stroke Education Film Viewing is the first listed.

NCT01909271 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01909271 about?

NCT01909271 is a clinical study titled "Tailored Approaches to Stroke Health Education". The overarching goal of the proposed intervention is to reduce stroke disparities by overcoming pre-hospital barriers related to emergency stroke treatment and facilitating the appropriate response to acute stroke using a novel culturally-tailored and sustainable approach developed by an experienced...

What is the current status of trial NCT01909271?

This trial is currently completed. It is a NA study. The enrollment target is 290 participants. The study started on 2014-04-16. Estimated completion is 2019-12.

What interventions are being tested in trial NCT01909271?

The interventions under investigation include: Stroke Education Film Viewing (BEHAVIORAL), Stroke Education Pamphlet Exposure (OTHER).

Who is sponsoring clinical trial NCT01909271?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01909271's enrollment target sits among peer trials

290 375th of 2000 higher than 1,625 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00775476 · 290 participants · Phase 2

    Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

  • NCT01874197 · 290 participants · NA

    Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic

  • NCT04331353 · 290 participants · NA

    The Allergen Reduction and Child Health Study (ARCHS)

  • NCT04649008 · 290 participants · Early Phase 1

    Localizing Epileptic Networks Using MRI and iEEG

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01909271, the US trial registry maintained by the National Library of Medicine. NCT01909271 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.